MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
ARCA biopharma Market Cap 2011-2026 | ABIO
As of March 02, 2026 ARCA biopharma has a market cap of $ 415 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap ARCA biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 484 M | 22.8 M | 30 M | 26.3 M | 25.4 M | 6.96 M | 6.09 M | 18.8 M | 23.1 M | 23.8 M | 14.6 M | 17.3 M | 9.07 M | 9.94 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 484 M | 6.09 M | 51.3 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M |  USA |
 |
Agenus
AGEN
|
215 K | $ 3.27 | -1.8 % | $ 1.17 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 29.33 | -2.98 % | $ 1.7 B | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.26 | -3.44 % | $ 324 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
79.3 B | $ 0.24 | 1.1 % | $ 5.73 B |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Aldeyra Therapeutics
ALDX
|
327 M | $ 5.49 | 0.52 % | $ 330 M | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alector
ALEC
|
247 M | $ 2.26 | -7.2 % | $ 233 M | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Aligos Therapeutics
ALGS
|
55.9 M | $ 7.02 | -0.21 % | $ 451 M | USA |
 |
Alkermes plc
ALKS
|
5.13 B | $ 29.32 | -2.61 % | $ 4.83 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
706 M | $ 2.57 | -7.73 % | $ 403 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 330.95 | -0.59 % | $ 43.4 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Altimmune
ALT
|
463 M | $ 4.2 | -2.55 % | $ 298 M | USA |
 |
ALX Oncology Holdings
ALXO
|
76.2 M | $ 2.11 | 0.09 % | $ 110 M | USA |
 |
Amgen
AMGN
|
198 B | $ 387.85 | 0.03 % | $ 209 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 20.22 | -0.05 % | $ 945 M | USA |
 |
Amarin Corporation plc
AMRN
|
440 M | $ 13.62 | -1.3 % | $ 5.55 B | Irlanda |
 |
AIM ImmunoTech
AIM
|
20.2 M | $ 0.92 | 5.25 % | $ 44.2 M | USA |
 |
AnaptysBio
ANAB
|
461 M | $ 54.61 | -0.8 % | $ 1.55 B | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 14.44 | 0.53 % | $ 212 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.2 B | $ 75.31 | 1.91 % | $ 1.45 B | USA |
 |
Annexon
ANNX
|
330 M | $ 5.38 | -3.93 % | $ 739 M | USA |
 |
Annovis Bio
ANVS
|
107 M | $ 2.6 | -2.99 % | $ 23.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Apellis Pharmaceuticals
APLS
|
2.77 B | $ 20.53 | -2.05 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 0.78 | -0.67 % | $ 4.25 M | China |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Aprea Therapeutics
APRE
|
21.4 M | $ 0.88 | -3.71 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
889 K | $ 7.28 | -0.55 % | $ 2.01 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aquestive Therapeutics
AQST
|
242 M | $ 3.99 | -0.15 % | $ 346 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
432 M | $ 8.11 | -1.44 % | $ 219 M |  Israel |
 |
Ardelyx
ARDX
|
1.62 B | $ 6.32 | -3.54 % | $ 1.52 B | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
13.8 B | $ 762.51 | -0.58 % | $ 25 B |  Niderland |